Pressmeddelande -
Governments get behind EIT Health-backed Stockholm3 prostate cancer test
The Stockholm3 test will become standard in Stockholm County and is funded for accelerated roll-out in the Nordic Countries
The Stockholm3 blood test, which provides more accurate diagnostics for prostate cancer and is supported by EIT Health, announced new government backing in two separate developments at the end of 2018: Stockholm3 will become a standard part of care provided in Stockholm County, and the team behind Stockholm3 is getting a €2.3 million grant to accelerate the roll-out of Stockholm3 in the Nordic countries.
STHLM3RS, an EIT Health Innovation Project and Success Story, was started in 2016 to support development of the new Stockholm3 blood test, which combines protein markers, genetic markers, clinical data and a multivariate algorithm to create a better screening for prostate cancer. Compared to current clinical practice using PSA, Stockholm3 identifies twice as many aggressive prostate cancers and reduces the risk of unnecessary prostate biopsies by 50%.
Standard in Stockholm
Stockholm County Council, an EIT Health Associate Partner, has decided to include the Stockholm3 test in standard clinical care. Stockholm County is the biggest county in Sweden, responsible for providing health care to 2 million Swedes.
Accelerated roll-out in the Nordic countries
A grant of €2.3 million has been provided by Nordforsk, an organisation of the Nordic Council of Ministers tasked with making the Nordic Region a global leader in research and innovation. The aim of the grant is to accelerate the roll-out of Stockholm3 in Norway, Denmark and Finland. The project will start in the first half of 2019 and run for two years.
For more information, please contact Martin Steinberg Project Leader of STHLM3RS. Martin.steinberg@ki.se.
EIT Health is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the fundamentals of healthcare and thus promote suitable future conditions for healthy living, active ageing and improved wellbeing of people across Europe. EIT Health leverages the expertise of more than 135 member organisations from the pharma, diagnostics and med tech fields, payers, insurances, research institutions and universities. As one of the EIT’s Knowledge and Innovation Communities (KICs), the initiative benefits from some of the world’s best-in-class academic and research organisations and offers both higher education and business expertise. By investing in Europe’s best entrepreneurial talents and ideas, EIT Health fosters the development and commercialization of smart product and service solutions in the health sector, addressing the challenges posed by demographic change and ageing societies.
Headquartered in Munich (Germany), EIT Health has six co-location centres in London (UK/Ireland), Stockholm (Scandinavia), Barcelona (Spain), Paris (France), Mannheim and Heidelberg (Germany/Switzerland) and Rotterdam (Belgium/Netherlands), as well as the “EIT Health InnoStars” cluster with partners linked to seven regions in six countries – Croatia, Hungary, Poland, Portugal, Italy and Wales.
EIT Health – Making healthy lives a reality for all
